BIOTECHNOLOGY & PUBLIC HEALTH
BIOTECHNOLOGY & PUBLIC HEALTH
Stacks Image 822
STRATEGIST. ANALYST. DEVELOPER. INNOVATOR.
Advancing biotechnologies for human health, environmental health, biodefense and national security, sustainable food production, nutrition, and conservation for over 20 years.
CO-FOUNDER & CHIEF EXECUTIVE OFFICER
PLANETARY GENETICS LLC
A private holding company and technology innovation engine advancing biotech startups and new ventures. Discover more at www.planetary-genetics.com.
PRINCIPAL CONSULTANT
ROSSI BIXBY + ASSOCIATES
Specialized consulting for biotechnology and biopharma companies addressing health, food, and the environment. Visit www.rossibixby.com to learn about our concierge services.
Stacks Image 849
STRATEGIST. ANALYST. DEVELOPER. INNOVATOR.
Advancing biotechnologies for human health, environmental health, biodefense and national security, sustainable food production, nutrition, and conservation for over 20 years.
CO-FOUNDER & CHIEF EXECUTIVE OFFICER
PLANETARY GENETICS LLC
A private holding company and technology innovation engine establishing biotech startups and new ventures. Discover more at www.planetary-genetics.com.
PRINCIPAL CONSULTANT
ROSSI BIXBY + ASSOCIATES
Specialized consulting for biotechnology and biopharma companies addressing health, food, and the environment. Visit www.rossibixby.com to learn about our concierge services.
HIGHLIGHTS
HIGHLIGHTS
TECHNOLOGY & BUSINESS STRATEGY
TECHNOLOGY & BUSINESS STRATEGY
  • Led strategic business and technology innovation functions at large publicly traded multi-national biotechnology company
  • Diligenced over $400M in biotechnology acquisitions (see list)
  • Served as technology and business analyst for FORBES 400 largest individual American biotech investor
  • Led strategic business and technology innovation functions at large publicly traded multi-national biotechnology company
  • Diligenced over $400M in biotechnology acquisitions (see list)
  • Served as technology and business analyst for FORBES 400 largest individual American biotech investor
  • Led strategic business and technology innovation functions at large publicly traded multi-national biotechnology company
  • Diligenced over $400M in biotechnology acquisitions (see list)
  • Served as technology and business analyst for FORBES 400 largest individual American biotech investor
CORPORATE STRATEGY | M&A DILIGENCE - click to read more
Advised C-suite executives on corporate technology strategy. Led internal, external, and open innovation functions to advance new product development, licensing, commercial partnerships, joint ventures, and strategic alliances for large publicly traded multi-national biotechnology company.

Learn more about corporate technology innovation strategy and M&A diligence experience supporting over $400M in biotechnology acquisitions:
Advised C-suite executives on corporate technology strategy. Led internal, external, and open innovation functions to advance new product development, licensing, commercial partnerships, joint ventures, and strategic alliances for large publicly traded multi-national biotechnology company.

Learn more about corporate technology innovation strategy and M&A diligence experience supporting over $400M in biotechnology acquisitions:
BIOTECHNOLOGY DEVELOPMENT & COMMERCIALIZATION
BIOTECHNOLOGY DEVELOPMENT & COMMERCIALIZATION
  • Marketed and advanced several FDA, USDA, and EPA regulated first-in-class gene-edited and genetically modified organisms for food, environmental, and public health applications (fish, fruit, insects, microbes)
  • Developed current FDA approved molecular tests ensuring safety of US blood supply (HIV, HCV, HBV, West Nile Virus)
  • Launched first FDA cleared combined Chlamydia and Gonorrhea molecular tests and Aptima molecular diagnostic platform
  • Marketed and advanced several FDA, USDA, and EPA regulated first-in-class gene-edited and genetically modified organisms for food, environmental, and public health applications (fish, fruit, insects, microbes)
  • Developed current FDA approved molecular tests ensuring safety of US blood supply (HIV, HCV, HBV, West Nile Virus)
  • Launched first FDA cleared combined Chlamydia and Gonorrhea molecular tests and Aptima molecular diagnostic platform
  • Marketed and advanced several FDA, USDA, and EPA regulated first-in-class gene-edited and genetically modified organisms for food, environmental, and public health applications (fish, fruit, insects, microbes)
  • Developed current FDA approved molecular tests ensuring safety of US blood supply (HIV, HCV, HBV, West Nile Virus)
  • Launched first FDA cleared combined Chlamydia and Gonorrhea molecular tests and Aptima molecular diagnostic platform
BIOTECHNOLOGY DEVELOPMENT & COMMERCIALIZATION - click to read more
Learn more about new product development experience:

Seeking investment for advancing new biotech ventures and technology development initiatives:
Learn more about new product development experience:

Seeking investment for advancing new biotech ventures and technology development initiatives:
PUBLIC HEALTH INNOVATION
PUBLIC HEALTH INNOVATION
  • Participated in transitioning of testing of US blood supply from immunoassay to more sensitive molecular testing
  • Facilitated protocol design and deployment of pioneering HIV/CD4 mobile testing in Sub-Saharan Africa to ensure efficacy of HIV anti-retroviral therapies (ART) in rural low resource settings
  • Performed global health fieldwork and international development in Sub-Saharan Africa with interventions targeting HIV, tuberculosis, malaria, malnutrition, sanitation, clean water, healthy air, agriculture, and health education to reduce burden of chronic and infectious diseases
  • Participated in transitioning of testing of US blood supply from immunoassay to more sensitive molecular testing
  • Facilitated protocol design and deployment of pioneering HIV/CD4 mobile testing in Sub-Saharan Africa to ensure efficacy of HIV anti-retroviral therapies (ART) in rural low resource settings
  • Performed global health fieldwork and international development in Sub-Saharan Africa with interventions targeting HIV, tuberculosis, malaria, malnutrition, sanitation, clean water, healthy air, agriculture, and health education to reduce burden of chronic and infectious diseases
  • Participated in transitioning of testing of US blood supply from immunoassay to more sensitive molecular testing
  • Facilitated protocol design and deployment of pioneering HIV/CD4 mobile testing in Sub-Saharan Africa to ensure efficacy of HIV anti-retroviral therapies (ART) in rural low resource settings
  • Performed global health fieldwork and international development in Sub-Saharan Africa with interventions targeting HIV, tuberculosis, malaria, malnutrition, sanitation, clean water, healthy air, agriculture, and health education to reduce burden of chronic and infectious diseases
PUBLIC HEALTH INNOVATION - click to read more
  • Helped flatten the curve on epidemic STIs and infectious diseases with development of Aptima molecular diagnostic platform
  • Developed biodefense and threat detection systems for bioterrorism agents and infectious diseases
  • Led corporate environmental biotechnology strategy, public health, and One Health initiatives under a former Commanding General of the US Army Corps of Engineers
  • Responded to epidemics including: COVID-19 pandemic, Zika, dengue, malaria, tuberculosis, HIV, influenza, Chlamydia, and Gonorrhea
  • Engaged federal, state, and local government agencies and briefed US Congress to advance high-profile new technologies for the public health
  • Advanced novel biotechnologies including:
  • Genetically engineered mosquitoes for vector control to reduce spread of Zika, dengue, yellow fever, chikungunya, and malaria
  • Viral-based vaccines for disease prevention and biodefense countermeasures
  • Environmental health interventions for bioremediation of emerging contaminants of concern (COCs)
  • Chronic disease diagnostic technologies for Alzheimer’s disease and cancer profiling
  • Genetically engineered salmon for more sustainable food production via aquaculture with reduced environmental impacts
  • Animal cloning of elite genetics to improve food systems and accessibility to quality protein
  • Helped flatten the curve on epidemic STIs and infectious diseases with development of Aptima molecular diagnostic platform
  • Developed biodefense and threat detection systems for bioterrorism agents and infectious diseases
  • Led corporate environmental biotechnology strategy, public health, and One Health initiatives under a former Commanding General of the US Army Corps of Engineers
  • Responded to epidemics including: COVID-19 pandemic, Zika, dengue, malaria, tuberculosis, HIV, influenza, Chlamydia, and Gonorrhea
  • Engaged federal, state, and local government agencies and briefed US Congress to advance high-profile new technologies for the public health
  • Advanced novel biotechnologies including:
  • Genetically engineered mosquitoes for vector control to reduce spread of Zika, dengue, yellow fever, chikungunya, and malaria
  • Viral-based vaccines for disease prevention and biodefense countermeasures
  • Environmental health interventions for bioremediation of emerging contaminants of concern (COCs)
  • Chronic disease diagnostic technologies for Alzheimer’s disease and cancer profiling
  • Genetically engineered salmon for more sustainable food production via aquaculture with reduced environmental impacts
  • Animal cloning of elite genetics to improve food systems and accessibility to quality protein
  • Helped flatten the curve on epidemic STIs and infectious diseases with development of Aptima molecular diagnostic platform
  • Developed biodefense and threat detection systems for bioterrorism agents and infectious diseases
  • Led corporate environmental biotechnology strategy, public health, and One Health initiatives under a former Commanding General of the US Army Corps of Engineers
  • Responded to epidemics including: COVID-19 pandemic, Zika, dengue, malaria, tuberculosis, HIV, influenza, Chlamydia, and Gonorrhea
  • Engaged federal, state, and local government agencies and briefed US Congress to advance high-profile new technologies for the public health
  • Advanced novel biotechnologies including:
  • Genetically engineered mosquitoes for vector control to reduce spread of Zika, dengue, yellow fever, chikungunya, and malaria
  • Viral-based vaccines for disease prevention and biodefense countermeasures
  • Environmental health interventions for bioremediation of emerging contaminants of concern (COCs)
  • Chronic disease diagnostic technologies for Alzheimer’s disease and cancer profiling
  • Genetically engineered salmon for more sustainable food production via aquaculture with reduced environmental impacts
  • Animal cloning of elite genetics to improve food systems and accessibility to quality protein
PROFILES
PROFILES
EXPERTISE | BUSINESS AREAS
EXPERTISE & PROFESSIONAL BIOTECH INDUSTRY EXPERIENCE
  • Corporate Strategy
  • Business and Technology Analysis
  • Corporate, Strategic, and Technical Communications
  • Marketing and Branding
  • Business Development and Strategic Alliances
  • Corporate Development and M&A Diligence
  • New Product Development and Commercialization
  • Basic and Applied Research
  • Public Health and Global Health Interventions and Messaging
  • Government Relations
  • Not-for-Profit and Philanthropic Engagements
  • Corporate Strategy
  • Business and Technology Analysis
  • Corporate, Strategic, and Technical Communications
  • Marketing and Branding
  • Business Development and Strategic Alliances
  • Corporate Development and M&A Diligence
  • New Product Development and Commercialization
  • Basic and Applied Research
  • Public Health and Global Health Interventions and Messaging
  • Government Relations
  • Not-for-Profit and Philanthropic Engagements
BUSINESS AREAS: HEALTH, FOOD & ENVIRONMENT
  • Medical diagnostics
  • Therapeutics
  • Vaccines
  • Sustainable food and protein production via genetic and genome engineering technologies
  • Environmental health technologies for:
  • Biosecurity, biothreat detection, and biodefense countermeasures (diagnostics, therapeutics, vaccines)
  • Infectious disease vector control
  • Bioremediation and environmental cleanup of contaminants of concern (COCs)
  • Carbon capture and up-cycling
  • Medical diagnostics
  • Therapeutics
  • Vaccines
  • Sustainable food and protein production via genetic and genome engineering technologies
  • Environmental health technologies for:
  • Biosecurity, biothreat detection, and biodefense countermeasures (diagnostics, therapeutics, vaccines)
  • Infectious disease vector control
  • Bioremediation and environmental cleanup of contaminants of concern (COCs)
  • Carbon capture and up-cycling
Experienced with fields and disciplines including:
  • Biotechnology Development
  • Biopharma
  • Medical Device and Healthcare Technologies
  • Synthetic Biology and Genetic Engineering
  • Public Health
  • Global Health
  • Epidemiology
  • Biodefense and Biosecurity
  • Environmental Health
  • One Health
  • Biotechnology Development
  • Biopharma
  • Medical Device and Healthcare Technologies
  • Synthetic Biology and Genetic Engineering
  • Public Health
  • Global Health
  • Epidemiology
  • Biodefense and Biosecurity
  • Environmental Health
  • One Health
BIOSKETCH
TODD BIXBY
TODD BIXBY
Mr. Bixby is a biotechnology developer, corporate strategist, life sciences and public health professional with over 20 years experience advancing biotechnologies to promote healthier communities and environments. He has worked to develop and deploy advanced technologies for human health, environmental health, biodefense and national security, nutrition, sustainable food production and agriculture, conservation, waste-to-value, alternative energies, and consumer products.

He has developed and launched groundbreaking FDA cleared products including current tests ensuring safety of U.S. blood supply, as well as pioneered deployment of advanced diagnostics for low resource settings in Sub-Saharan Africa. He has also advanced several genetic engineering technologies, as well as first-in-class gene-edited and genetically engineered organism products regulated by FDA, USDA, EPA, and reviewed by the CDC.

Mr. Bixby has multi-disciplinary expertise in corporate strategy, business and corporate development, M&A diligence, technology analysis, new product development, basic and applied research, project management, marketing and communications, strategic alliances, commercialization, and leading teams.

He is also a great proponent of interventions aimed at Public Health, One Health and Planetary Health.
Mr. Bixby is a biotechnology developer, corporate strategist, life sciences and public health professional with over 20 years experience advancing biotechnologies to promote healthier communities and environments. He has worked to develop and deploy advanced technologies for human health, environmental health, biodefense and national security, nutrition, sustainable food production and agriculture, conservation, waste-to-value, alternative energies, and consumer products.

He has developed and launched groundbreaking FDA cleared products including current tests ensuring safety of U.S. blood supply, as well as pioneered deployment of advanced diagnostics for low resource settings in Sub-Saharan Africa. He has also advanced several genetic engineering technologies, as well as first-in-class gene-edited and genetically engineered organism products regulated by FDA, USDA, EPA, and reviewed by the CDC.

Mr. Bixby has multi-disciplinary expertise in corporate strategy, business and corporate development, M&A diligence, technology analysis, new product development, basic and applied research, project management, marketing and communications, strategic alliances, commercialization, and leading teams.

He is also a great proponent of interventions aimed at Public Health, One Health and Planetary Health.
CURRENT COMPANIES
PLANETARY GENETICS
PLANETARY GENETICS
A private holding company and technology innovation engine advancing biotech startups and new ventures.
A private holding company and technology innovation engine advancing biotech startups and new ventures.
ROSSI BIXBY + ASSOCIATES | BIOTECHNOLOGY & COMMUNICATIONS CONSULTING
ROSSI BIXBY + ASSOCIATES | BIOTECHNOLOGY & COMMUNICATIONS CONSULTING
Specialized consulting for biotechnology and biopharma companies addressing health, food, and the environment.
Specialized consulting for biotechnology and biopharma companies addressing health, food, and the environment.
SOCIAL MEDIA
TODD BIXBY
TODD BIXBY
PLANETARY GENETICS
PLANETARY GENETICS
ROSSI BIXBY + ASSOCIATES | BIOTECHNOLOGY & COMMUNICATIONS CONSULTING
ROSSI BIXBY + ASSOCIATES | BIOTECHNOLOGY & COMMUNICATIONS CONSULTING

ADVANCING BIOTECHNOLOGY
FOR PUBLIC HEALTH,
ONE HEALTH AND
PLANETARY HEALTH

ADVANCING BIOTECHNOLOGY FOR PUBLIC HEALTH, ONE HEALTH AND PLANETARY HEALTH

Stacks Image 152
We can’t solve problems by using the same kind of thinking we used when we created them.
A.E.
We can’t solve problems by using the same kind of thinking we used when we created them.
A.E.

Learn more about biotechnology development experience and affiliations here.

Contact:
info@toddbixby.com
Learn more about biotechnology development experience and affiliations here.
Contact:
info@toddbixby.com